Prem S. Shah - Aug 31, 2022 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
EVP and Co-President of Retail
Signature
/s/ Prem S. Shah
Stock symbol
CVS
Transactions as of
Aug 31, 2022
Transactions value $
$0
Form type
4
Date filed
9/2/2022, 04:47 PM
Previous filing
Jun 30, 2022
Next filing
Mar 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock (RSU) Award $0 +20.4K $0.00 20.4K Aug 31, 2022 Direct F1
holding CVS Common Stock 43.5K Aug 31, 2022 Direct
holding CVS Common Stock (pep) 4.44K Aug 31, 2022 Direct F2
holding CVS Common Stock (restricted) 16.5K Aug 31, 2022 Direct
holding CVS ESOP Common Stock 4.54K Aug 31, 2022 Direct
holding CVS Common Stock (restricted) 2.83K Aug 31, 2022 Direct F3
holding CVS Stock Unit (deferred) 6.67K Aug 31, 2022 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Stock Option 2.94K Aug 31, 2022 Common Stock 2.94K $104.82 Direct F5
holding CVS Stock Option 846 Aug 31, 2022 Common Stock 846 $62.21 Direct F6
holding CVS Stock Option 9.47K Aug 31, 2022 Common Stock 9.47K $54.19 Direct F7
holding CVS Stock Option 28.6K Aug 31, 2022 Common Stock 28.6K $58.34 Direct F8
holding CVS Stock Option 28.7K Aug 31, 2022 Common Stock 28.7K $74.30 Direct F9
holding CVS Stock Option 41.6K Aug 31, 2022 Common Stock 41.6K $101.09 Direct F10
holding CVS Stock Option 26.6K Aug 31, 2022 Common Stock 26.6K $75.24 Direct F11
holding CVS Phantom Stock Credits 11.3K Aug 31, 2022 Common Stock 11.3K $1.00 Direct F12, F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of RSUs awarded pursuant to the Issuer's 2017 Stock Incentive Plan. Restrictions lapse on the third anniversary of the grant date.
F2 Consists of Matching RSUs awarded pursuant to Issuer's Partnership Equity Program, a sub-plan under its ICP, and dividend equivalents on the Matching RSUs. Restrictions lapse on the RSUs on 08/31/2023.
F3 Consists of RSUs awarded pursuant to Issuer's Performance-Based Restricted Stock Plan under its 2017 Incentive Compensation Plan. Restrictions on the 2018 grant lapse in three equal installments commencing on 02/26/2022; restrictions on the 2020 grant lapse in two equal installments commencing on 2/28/22.
F4 Consists of Stock Units awarded pursuant to Issuer's 2010 & 2017 Incentive Compensation Plans, the receipt of which the reporting person has elected to defer.
F5 Option became exercisable in four equal installments commencing 04/01/2017.
F6 Option became exercisable in four equal installments commencing 04/01/2019. Additional options from this award have been exercised.
F7 Option becomes exercisable in four equal installments commencing 04/01/2020. Additional options from this award have been exercised.
F8 Option becomes exercisable in four equal installments commencing 04/01/2021. Additional options from this award have been exercised.
F9 Option became exercisable in three equal installments commencing 04/01/2022.
F10 Option becomes exercisable in four equal installments, commencing 4/1/2023.
F11 Option vests in three equal installments, on 8/31/2021, 8/31/2022 and 8/31/2023.
F12 Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
F13 Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.